Venetoclax plus pediatric regimen in adolescents and adults with Ph-negative acute lymphoblastic leukemia.

Venetoclax combined with pediatric-inspired chemotherapy achieves a 91% remission rate and improves survival in adolescents and adults with newly diagnosed Ph-negative ALL.

• Why it matters: Effective first-line treatments for Ph-negative ALL are limited, and improving remission and survival rates is critical for better patient outcomes.
• What they did: A prospective phase 2 trial enrolled 167 patients aged 14-60, administering venetoclax with chemotherapy and measuring MRD negativity after induction.
• The result: The combination resulted in high remission and MRD negativity rates, with 2-year survival estimates over 76%, demonstrating a manageable safety profile and superior outcomes compared to historical controls.